Propanc Biopharma Inc
OTC:PPCB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Grupo Aeromexico SAB de CV
NYSE:AERO
|
MX |
|
Takemoto Yohki Co Ltd
TSE:4248
|
JP |
|
E
|
e-Muzyka SA
WSE:EMU
|
PL |
Propanc Biopharma Inc
Accounts Payable
Propanc Biopharma Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Propanc Biopharma Inc
OTC:PPCB
|
Accounts Payable
$1.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Accounts Payable
$33.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
CSL Ltd
ASX:CSL
|
Accounts Payable
$3.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Accounts Payable
AU$167.8k
|
CAGR 3-Years
-32%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Accounts Payable
AU$71.7m
|
CAGR 3-Years
62%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Accounts Payable
AU$9.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
69%
|
CAGR 10-Years
33%
|
|
Propanc Biopharma Inc
Glance View
Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate PRP is a pharmaceutical composition consisting of two pancreatic proenzymes trypsinogen and chymotrypsinogen for treating cancer. PRP is an approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that targets and eradicates cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. PRP is a therapy based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas and could represent the body’s primary defense against cancer.
See Also
What is Propanc Biopharma Inc's Accounts Payable?
Accounts Payable
1.3m
USD
Based on the financial report for Jun 30, 2024, Propanc Biopharma Inc's Accounts Payable amounts to 1.3m USD.
What is Propanc Biopharma Inc's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
9%
Over the last year, the Accounts Payable growth was 29%. The average annual Accounts Payable growth rates for Propanc Biopharma Inc have been 9% over the past three years .
